GlaxoSmithKline submits application for COPD drug in EU
GlaxoSmithKline (GSK) has submitted a regulatory application in the EU for umeclidinium monotherapy, an investigative once-daily medicine used in patients with chrinic obstructive pulmonary disease (COPD).
GlaxoSmithKline (GSK) has submitted a regulatory application in the EU for umeclidinium monotherapy, an investigative once-daily medicine used in patients with chrinic obstructive pulmonary disease (COPD).
The treatment, which is administered using the company's Ellipta inhaler, is designed to relive symptoms in adult suffers of COPD.
The group said a marketing authoristion application (MAA) for the treatment has been submitted to the European Medicines Agency (EMA).
Regulatory filings for the product are imminent in the US and planned in other countries during the course of 2013, it added.
The share price was down 0.36% to 1,676p by 11:00 on Friday.
NR